Tyrosine Supplementation Rescues a Growth Defect in a Humanized

Nancy Sun, Tristan N Samuels, Kyle Hoffman, Ridhwan Busari, Zain Nasir, Nicole Girard, Noah M Reynolds, Ilka U Heinemann

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nancy SunDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 3K7, Canada.

Tristan N SamuelsDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 3K7, Canada.ORCID 0009-0006-6346-4699

Kyle HoffmanBioinformatics Solutions Inc., Waterloo, ON N2L 3K8, Canada.

Ridhwan BusariDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 3K7, Canada.

Zain NasirDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 3K7, Canada.ORCID 0009-0003-8395-5290

Nicole GirardSchool of Integrated Science, Sustainability, and Public Health, University of Illinois Springfield, Springfield, IL 62703, USA.

Noah M ReynoldsSchool of Integrated Science, Sustainability, and Public Health, University of Illinois Springfield, Springfield, IL 62703, USA.

Ilka U HeinemannDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 3K7, Canada.ORCID 0000-0003-1721-1667

Funding

CIHR 185961ENRICH Doctoral Fellowship n/aNatural Sciences and Engineering Research Council of Canada 04776Natural Sciences and Engineering Research Council of Canada 04835Rare Disease Models and Mechanisms n/a

6 · The paper itself

Abstract

Dominant pathogenic mutations in tyrosyl-tRNA synthetase (YARS1) are associated with Charcot-Marie-Tooth disease (CMT), a progressive peripheral neuropathy for which no disease-modifying therapies currently exist. While recent advances in amino acid supplementation therapies suggest potential benefit for recessive aminoacyl-tRNA synthetase disorders, their applicability to dominant

Indexed as

Charcot-Marie-Tooth DiseaseSaccharomyces cerevisiaeTyrosineTyrosine-tRNA LigaseHumansMutationTyrosineTyrosine-tRNA Ligaseamino acid supplementationaminoacyl-tRNA synthetaseARS diseasetransfer RNA

Identifiers

PMID42653481

DOI10.3390/ijms27167481

PMCPMC13513244

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.